Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
“The good performance we saw in the third quarter has continued to further improve.
A group of unions and consumer organizations have banded together in opposition to the $63 billion merger citing concerns that it will create a monopoly and harm competition.
David Roth, Chief Financial Officer of 4basebio AG, comments: “4basebio can now successfully acquire the desired number of shares in full.
Sale reflects culmination of successful CDMO strategy initiated in 2015 and 59 percent 5-year CAGR of Masthercell under Orgenesis’ leadership
Revolution Medicines snagged $238 million through its initial public offering to support the development of the company’s pipeline of drugs that target the RAS pathway, including its lead clinical candidate.
Summit Therapeutics plc announced that it achieved the first milestone under its license and collaboration agreement with Eurofarma Laboratórios SA.
Funding to support GMP adenovirus manufacture for a first-in-human basket clinical trial in melanoma, lung cancer, and triple negative breast cancer
Valeritas and its subsidiaries filed for Chapter 11 bankruptcy on February 9, 2020 in the District of Delaware. At the same time, Zealand entered into the definitive deal to buy the assets.
Founded by UKI2S with co-investment from LifeArc & Parkwalk to advance a diabetic macular edema gene therapy and other pipeline products
Microbix Biosystems Inc., a life sciences innovator making critical ingredients that enable the production of clinical diagnostics and creating medical devices that help ensure test accuracy, announces that it has completed a non-brokered private placement financing with gross proceeds of $2,355,000, by issuing an aggregate of 11,775,000 units at a price of $0.20 per Unit.